



**FOR RELEASE, October 8, 2007**

**Contact:** Trinity Biotech plc  
Rory Nealon  
(353) -1-2769800  
e-mail: [rory.nealon@trinitybiotech.com](mailto:rory.nealon@trinitybiotech.com)

## **Trinity Biotech Notifies Irish Stock Exchange of Shareholder Decision to Delist.**

DUBLIN, IRELAND-- (MARKET WIRE)— October 8, 2007 -- Trinity Biotech plc (NASDAQ:[TRIB](#) - [News](#)) (DUBLIN: TRIB.I), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today notifies the Irish Stock Exchange of its decision to delist from the Irish Stock Exchange.

Pursuant to an EGM on Monday 1 October the shareholders of Trinity Biotech plc voted in favour of delisting from the Irish Stock Exchange. The Company hereby gives 20 business days notice of its decision to delist and expects that this will take effect from Monday 5 November, 2007. This will have no effect on the Nasdaq listing of the Company upon which 98% of all trading in the Company's shares takes place.

Trinity Biotech develops, acquires, manufactures and markets over 500 diagnostic products for the point-of-care and clinical laboratory segments of the diagnostic market. The broad line of test kits is used to detect infectious diseases, sexually transmitted diseases, blood coagulation disorders, and autoimmune diseases. Trinity Biotech sells worldwide in over 80 countries through its own sales force and a network of international distributors and strategic partners. For further information please see the Company's website: [www.trinitybiotech.com](http://www.trinitybiotech.com).

Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialization and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.